Adebrelimab
Product Specifications
UNSPSC Description
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].
Target Antigen
Apoptosis; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Apoptosis;Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/adebrelimab.html
Purity
97.84
Solubility
10 mM in DMSO
Smiles
[Adebrelimab]
References & Citations
[1]Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.|[2]Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99422/Adebrelimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99422/Adebrelimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 4
CAS Number
2247114-85-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
